Drug intelligence / Profile preview

cyclotheonamide a

Development stage
Preclinical
Modality
Peptides, Small Molecules
01

Overview

Cyclotheonamide A is a naturally occurring cyclic peptide isolated from the marine sponge Theonella. It features a unique structure with a cyclic arrangement of amino acids and has attracted interest in medicinal chemistry due to its potential pharmacological properties—including antimicrobial and cytotoxic effects. Cyclotheonamide A is notable for its ability to inhibit specific enzymes and cellular processes; it has been studied as an inhibitor of serine proteases such as trypsin and thrombin by binding to their active sites. Its complex structure contributes to its biological activity but also presents challenges for extraction and synthesis. Cyclotheonamide A remains an experimental compound with no approved clinical indications[1][2][5][6].

Other names
2Y1TEH8EW7UNII-2Y1TEH8EW7UNII2Y1TEH8EW7UNII 2Y1TEH8EW7129033-04-1CYCLOTHEONAMIDE A [MI]3-((4-Amino-5-(4-hydroxyphenyl)-1-oxo-2-pentenyl)amino)-N-formyl-L-alanyl-D-prolyl-6-((aminoiminomethyl)amino)-2-oxo-3-aminohexanoyl-L-phenylalanine cyclic (4–1)-peptideN-[(3S,7E,9S,12R,16S,19S)-12-benzyl-16-[3-(diaminomethylideneamino)propyl]-9-[(4-hydroxyphenyl)methyl]-2,6,11,14,15,18-hexaoxo-1,5,10,13,17-pentazabicyclo[17.3.0]docos‑7-en‑3-yl]formamide
02

Targets

SK (Streptokinase)F2 (Thrombin)PRSS1 (Trypsin family)

Beyond the preview

Go deeper on cyclotheonamide a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclotheonamide a.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call